Moderna's RSV Vaccine for Seniors Wins FDA Approval
TL;DR Summary
Despite FDA approval of its new RSV vaccine, Moderna's stock fell due to prior over-enthusiasm for its AI initiatives and competition from established vaccines by GSK and Pfizer. The new vaccine's similar efficacy and storage disadvantages, combined with high R&D expenses and declining sales of Spikevax, make Moderna a risky buy despite its cash reserves and potential future pipeline successes.
- Is Moderna Stock a Buy Now That It's a 2-Product Company? The Motley Fool
- Moderna Investors Just Got Some Bullish News Yahoo Finance
- FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product CNBC
- FDA approves Moderna’s mRNA RSV vaccine for older adults CNN
- Moderna's RSV shot wins FDA approval for use in older adults The Seattle Times
Reading Insights
Total Reads
0
Unique Readers
24
Time Saved
4 min
vs 4 min read
Condensed
92%
773 → 60 words
Want the full story? Read the original article
Read on The Motley Fool